AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31713056 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured daily hip exercise regimen (extension and external rotation)
Number of subjects: 8
Study 31713056 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 8
Study 31713130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 43
Study 31713130 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 43
Study 31713160 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin monotherapy
Number of subjects: 2235
Study 31713310 — intervention group
Group type: EXPERIMENTAL
Intervention: GORE® Carotid Stent (GCS)
Number of subjects: 312
Study 31714428 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of antiretroviral therapy use (particularly related to protease inhibitor use)
Number of subjects: 18
Study 31714428 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of HIV
Number of subjects: 18
Study 31714428 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 T-cell count
Number of subjects: 18
Study 31714428 — intervention group
Group type: COMPARATOR
Intervention: HIV viral load
Number of subjects: 18
Study 31714987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 30
Study 31715023 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative patients who developed early POCD (n=24, 19.4%)
Number of subjects: 124
Study 31715023 — intervention group
Group type: COMPARATOR
Intervention: Non-POCD patients
Number of subjects: 124
Study 31717747 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid biopsy using CellSearch
Number of subjects: 22
Study 31717747 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid biopsy combining several biomarkers
Number of subjects: 22
Study 31717747 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CTC and exosome detection
Number of subjects: 22
Study 31718316 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31718534 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 immunization
Number of subjects: 0
Study 31718534 — intervention group
Group type: COMPARATOR
Intervention: PPV23 immunization
Number of subjects: 0
Study 31718666 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA (Optical Coherence Tomography Angiography)
Number of subjects: 140
Study 31718666 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravital capillaroscopy
Number of subjects: 140
Study 31718666 — intervention group
Group type: COMPARATOR
Intervention: OCTA
Number of subjects: 140
Study 31718666 — intervention group
Group type: COMPARATOR
Intervention: LEPCs function
Number of subjects: 140
Study 31718676 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum AcPGP concentrations
Number of subjects: 182
Study 31718676 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma AcPGP concentrations
Number of subjects: 182
Study 31719001 — intervention group
Group type: EXPERIMENTAL
Intervention: MPI
Number of subjects: 49
Study 31719001 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 49
Study 31719001 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction models
Number of subjects: 49
Study 31719030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit Plus app enhanced with a face-to-face LifeSteps session
Number of subjects: 60
Study 31719030 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 60
Study 31719069 — intervention group
Group type: EXPERIMENTAL
Intervention: Late chronotype
Number of subjects: 2247
Study 31719069 — intervention group
Group type: COMPARATOR
Intervention: Early chronotype
Number of subjects: 2247
Study 31719069 — intervention group
Group type: EXPERIMENTAL
Intervention: All chronotypes (categorical variable)
Number of subjects: 2247
Study 31719069 — intervention group
Group type: EXPERIMENTAL
Intervention: All chronotypes (continuous variable)
Number of subjects: 2247
Study 31719077 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose of opioids with NSAIDs
Number of subjects: 159
Study 31719077 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% overall reduction in opioid dosage, dose-extending placebos and NSAIDs
Number of subjects: 159
Study 31719077 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs and placebos
Number of subjects: 159
Study 31719258 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of serum cystatin C levels
Number of subjects: 638
Study 31719258 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of serum cystatin C levels
Number of subjects: 638
Study 31719684 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS metastasis-free survival (CNSM-FS)
Number of subjects: 16703
Study 31719684 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) after CNS metastasis diagnosis
Number of subjects: 16703
Study 31720000 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath tests
Number of subjects: 50
Study 31720254 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed enriched yogurt (200 g 2.5% fat yogurt containing 30-g flaxseed)
Number of subjects: 57
Study 31720254 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed enriched yogurt
Number of subjects: 57
Study 31720254 — intervention group
Group type: COMPARATOR
Intervention: Plain yogurt (control)
Number of subjects: 57
Study 31720293 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Trelegy) delivered by the ELLIPTA inhaler, once daily for 24 weeks
Number of subjects: 0
Study 31720962 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD discussions during routine visits
Number of subjects: 48
Study 31720962 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD awareness assessment
Number of subjects: 48
Study 31720962 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up CKD awareness
Number of subjects: 48
Study 31721017 — intervention group
Group type: EXPERIMENTAL
Intervention: Spebrutinib 375 mg/day
Number of subjects: 47
Study 31721017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31721213 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest
Number of subjects: 0
Study 31721246 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) monotherapy withdrawal over ~6 months
Number of subjects: 15
Study 31721246 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) monotherapy withdrawal
Number of subjects: 15
Study 31721246 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy gene signature
Number of subjects: 15
Study 31721246 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy staining at study end
Number of subjects: 15
Study 31721643 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1,200 mg and Bevacizumab 15 mg/kg intravenously every 3 weeks
Number of subjects: 60
Study 31722205 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-α
Number of subjects: 0
Study 31722205 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased IFNAR1 surface expression
Number of subjects: 0
Study 31722671 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver
Number of subjects: 134
Study 31722680 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered pharmacist care (comprehensive review at months 3 and 5)
Number of subjects: 72
Study 31722685 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS) training for ETT localization
Number of subjects: 0
Study 31722685 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care methods for ETT localization
Number of subjects: 0
Study 31722736 — intervention group
Group type: EXPERIMENTAL
Intervention: MDSCs obtained at and beyond 14 days post-sepsis
Number of subjects: 267
Study 31722736 — intervention group
Group type: EXPERIMENTAL
Intervention: MDSCs obtained at various intervals over 6 weeks
Number of subjects: 267
Study 31722951 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy applied to craniomandibular structures, with four weekly sessions.
Number of subjects: 100
Study 31723056 — intervention group
Group type: EXPERIMENTAL
Intervention: Labyrinth Devices Multichannel Vestibular Implant System vestibular implant
Number of subjects: 4
Study 31723443 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabic linguistic version of the Overactive Bladder Symptoms Score questionnaire
Number of subjects: 0
Study 31723723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women in the second trimester
Number of subjects: 0
Study 31723723 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 0
Study 31723723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women during pregnancy and 6 months postpartum
Number of subjects: 0
Study 31723767 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib in combination with Rituximab (IR)
Number of subjects: 0
Study 31723767 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib in combination with Bendamustine (IB)
Number of subjects: 0
Study 31723767 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib in combination with both Rituximab and Bendamustine (IBR)
Number of subjects: 0
Study 31723837 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment of iron load
Number of subjects: 243
Study 31724050 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to Severe (M/S) influenza
Number of subjects: 1478
Study 31724050 — intervention group
Group type: COMPARATOR
Intervention: Mild disease
Number of subjects: 1478
Study 31724339 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST
Number of subjects: 9
Study 31724339 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST + GHA
Number of subjects: 9
Study 31724339 — intervention group
Group type: COMPARATOR
Intervention: CTRL
Number of subjects: 9
Study 31724813 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib (600 µg/m) in combination with low-dose temozolomide (TMZ)
Number of subjects: 40
Study 31725015 — intervention group
Group type: EXPERIMENTAL
Intervention: BET inhibitor apabetalone
Number of subjects: 0
Study 31725015 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31725157 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustainable Diet Index (SDI) Q1 (lowest sustainability)
Number of subjects: 15626
Study 31725157 — intervention group
Group type: COMPARATOR
Intervention: Sustainable Diet Index (SDI) Q5 (highest sustainability)
Number of subjects: 15626
Study 31725351 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for up to 2 years
Number of subjects: 124
Study 31725351 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 124
Study 31725442 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31725459 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy for 78 weeks
Number of subjects: 683
Study 31725531 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation support
Number of subjects: 24
Study 31726319 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure monitoring in patients with orthostatic hypotension (OH)
Number of subjects: 0
Study 31726319 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure variability assessment
Number of subjects: 0
Study 31726319 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 0
Study 31726422 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i)
Number of subjects: 5006
Study 31726422 — intervention group
Group type: COMPARATOR
Intervention: High-intensity statins
Number of subjects: 5006
Study 31726422 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 5006
Study 31726452 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT-A injection
Number of subjects: 100
Study 31727019 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral elective nodal irradiation (ENI) selected by lymph drainage mapping using SPECT/CT
Number of subjects: 0
Study 31727019 — intervention group
Group type: COMPARATOR
Intervention: Bilateral elective nodal irradiation (ENI)
Number of subjects: 0
Study 31727075 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 79
Study 31727113 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab-emtansine (T-DM1)
Number of subjects: 154
Study 31727136 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR pre-OP
Number of subjects: 36
Study 31727136 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR 3-5 days post-OP
Number of subjects: 36
Study 31727136 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR 6-11 days post-OP
Number of subjects: 36
Study 31727136 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP pre-OP
Number of subjects: 36
Study 31727136 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP 6-11 days post-OP
Number of subjects: 36
Study 31727136 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of suPAR and CRP
Number of subjects: 36
Study 31727169 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid positron emission tomography (PET) imaging
Number of subjects: 271
Study 31727169 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathological and biochemical examination of Aβ pathology
Number of subjects: 271
Study 31727669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation/analgesia (SA)
Number of subjects: 40
Study 31727669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil and midazolam
Number of subjects: 40
Study 31727669 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 40
Study 31727669 — intervention group
Group type: EXPERIMENTAL
Intervention: SA premedication
Number of subjects: 40
Study 31727669 — intervention group
Group type: EXPERIMENTAL
Intervention: SA
Number of subjects: 40
Study 31727669 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 40
Study 31727685 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma linoleic acid (LA)
Number of subjects: 3257
Study 31727685 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary linoleic acid (LA)
Number of subjects: 3257
Study 31728032 — intervention group
Group type: EXPERIMENTAL
Intervention: High Atherogenic Index of Plasma (AIP)
Number of subjects: 2485
Study 31728032 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident AIP group
Number of subjects: 2485
Study 31728032 — intervention group
Group type: COMPARATOR
Intervention: Normal AIP at baseline and elevated AIP in 2013
Number of subjects: 2485
Study 31728500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary pulses with or without other legumes
Number of subjects: 83284
Study 31728837 — intervention group
Group type: EXPERIMENTAL
Intervention: INHD
Number of subjects: 67
Study 31728837 — intervention group
Group type: COMPARATOR
Intervention: CHD (Control)
Number of subjects: 67
Study 31729626 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib (150 mg single oral dose)
Number of subjects: 0
Study 31729979 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes (HbA1c between 5.7 and 6.4%)
Number of subjects: 6688
Study 31729979 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes (HbA1c between 5.7 and 6.4%) with 3 or more cardiovascular risk factors
Number of subjects: 6688
Study 31729979 — intervention group
Group type: EXPERIMENTAL
Intervention: Males with prediabetes
Number of subjects: 6688
Study 31730043 — intervention group
Group type: EXPERIMENTAL
Intervention: M-Cubed (M3) app for a period of three months
Number of subjects: 1229
Study 31730043 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control (delayed access to M3 app)
Number of subjects: 1229
Study 31730164 — intervention group
Group type: EXPERIMENTAL
Intervention: IV administration of ertapenem (1 g once daily)
Number of subjects: 26
Study 31730380 — intervention group
Group type: EXPERIMENTAL
Intervention: Young women with breast cancer (≤ 40 years)
Number of subjects: 2888
Study 31730380 — intervention group
Group type: COMPARATOR
Intervention: Older women with breast cancer (> 40 years)
Number of subjects: 2888
Study 31730450 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention and care services access
Number of subjects: 186
Study 31730450 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-engagement strategies and gender-affirming research methods
Number of subjects: 186
Study 31730497 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) including methotrexate (MTX)
Number of subjects: 172
Study 31730497 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 172
Study 31730497 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of erosions at baseline
Number of subjects: 172
Study 31730497 — intervention group
Group type: EXPERIMENTAL
Intervention: HAQ-DI ≥1 at inclusion and active smoking
Number of subjects: 172
Study 31730687 — intervention group
Group type: EXPERIMENTAL
Intervention: rurioctocog alfa pegol (9 patients on prophylaxis, 1 patient on-demand)
Number of subjects: 10
Study 31731085 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 1246
Study 31731085 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in BMI
Number of subjects: 1246
Study 31731085 — intervention group
Group type: EXPERIMENTAL
Intervention: Per stage increase of CRF
Number of subjects: 1246
Study 31731085 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CRF in obese children
Number of subjects: 1246
Study 31732519 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanized anti-CD19 scFv CAR-T (hCAR-T)
Number of subjects: 10
Study 31732566 — intervention group
Group type: EXPERIMENTAL
Intervention: Apathy rating scores
Number of subjects: 64
Study 31732566 — intervention group
Group type: EXPERIMENTAL
Intervention: β-amyloidopathy
Number of subjects: 64
Study 31732566 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional brain findings
Number of subjects: 64
Study 31732655 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 232353
Study 31732655 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 232353
Study 31732655 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased prescription of P2Y
Number of subjects: 232353
Study 31732715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.5 mg/kg) over 40 minutes
Number of subjects: 39
Study 31733180 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban at a dose of 10 mg daily (with aspirin at a dose of 75 to 100 mg daily for the first 3 months)
Number of subjects: 1644
Study 31733180 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet group (aspirin at a dose of 75 to 100 mg daily with clopidogrel at a dose of 75 mg daily for the first 3 months)
Number of subjects: 1644
Study 31734214 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk plaque (HRP) lesions with ≥2 features of positive remodeling, spotty calcification, or low-attenuation plaque.
Number of subjects: 1297
Study 31734214 — intervention group
Group type: COMPARATOR
Intervention: Non-HRP lesions.
Number of subjects: 1297
Study 31734214 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline total PAV and %DS.
Number of subjects: 1297
Study 31734214 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HRP.
Number of subjects: 1297
Study 31734525 — intervention group
Group type: EXPERIMENTAL
Intervention: NPSR1 T risk allele carriers
Number of subjects: 121
Study 31734525 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC) with A/A genotype
Number of subjects: 121
Study 31734525 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with one or two T alleles
Number of subjects: 121
Study 31734620 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective sleep continuity
Number of subjects: 0
Study 31734620 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective sleep disturbance
Number of subjects: 0
Study 31734695 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational assays for N. gonorrhoeae and C. trachomatis detection
Number of subjects: 2598
Study 31734781 — intervention group
Group type: COMPARATOR
Intervention: NaF PET/CT-derived values
Number of subjects: 136
Study 31734781 — intervention group
Group type: COMPARATOR
Intervention: Framingham risk score patterns
Number of subjects: 136
Study 31734820 — intervention group
Group type: EXPERIMENTAL
Intervention: Dotinurad 1 mg for 7 days
Number of subjects: 12
Study 31734820 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 80 mg (concomitant use with Dotinurad)
Number of subjects: 12
Study 31734832 — intervention group
Group type: EXPERIMENTAL
Intervention: RO6839921 (14-120 mg AP)
Number of subjects: 41
Study 31734899 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 199
Study 31734899 — intervention group
Group type: COMPARATOR
Intervention: Reference infliximab
Number of subjects: 199
Study 31735436 — intervention group
Group type: EXPERIMENTAL
Intervention: DOACs (apixaban, rivaroxaban, dabigatran, edoxaban)
Number of subjects: 434
Study 31735436 — intervention group
Group type: COMPARATOR
Intervention: VKAs (warfarin, acenocoumarol)
Number of subjects: 434
Study 31735436 — intervention group
Group type: EXPERIMENTAL
Intervention: DOACs
Number of subjects: 434
Study 31735660 — intervention group
Group type: EXPERIMENTAL
Intervention: qSOFA
Number of subjects: 713
Study 31735660 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRS
Number of subjects: 713
Study 31735660 — intervention group
Group type: EXPERIMENTAL
Intervention: CRB
Number of subjects: 713
Study 31735660 — intervention group
Group type: EXPERIMENTAL
Intervention: CRB-65
Number of subjects: 713
Study 31735660 — intervention group
Group type: EXPERIMENTAL
Intervention: DS CRB-65
Number of subjects: 713
Study 31735691 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 445
Study 31736826 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby Triple P (BTP) Positive Parenting Program
Number of subjects: 49
Study 31736826 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 49
Study 31737275 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week individualized cervicovestibular rehabilitation program
Number of subjects: 46
Study 31737275 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach of gradual sub-threshold physical activation (SPA) alone
Number of subjects: 46